Captrust Financial Advisors Cara Therapeutics, Inc. Transaction History

Captrust Financial Advisors

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.67 - $3.33 $1,987 - $3,962	-1,190 Reduced 6.96%	15,918 $26,000
Q2 2023 Aug 14, 2023	BUY	$2.83 - $4.94 $1,723 - $3,008	609 Added 3.69%	17,108 $48,000
Q1 2023 May 15, 2023	BUY	$4.89 - $12.27 $2,156 - $5,411	441 Added 2.75%	16,499 $81,000
Q4 2022 Feb 15, 2023	BUY	$8.88 - $12.77 $142,595 - $205,060	16,058 New	16,058 $172,000
Q2 2022 Aug 16, 2022	SELL	$7.45 - $13.84 $11,808 - $21,936	-1,585 Reduced 60.43%	1,038 $9,000
Q1 2022 May 16, 2022	BUY	$9.94 - $12.65 $11,341 - $14,433	1,141 Added 76.99%	2,623 $32,000
Q4 2021 Feb 14, 2022	SELL	$11.99 - $18.14 $2,997 - $4,535	-250 Reduced 14.43%	1,482 $18,000
Q3 2021 Nov 16, 2021	BUY	$11.55 - $16.06 $20,004 - $27,815	1,732 New	1,732 $27,000
Q2 2021 Aug 16, 2021	SELL	$12.38 - $29.19 $37,140 - $87,570	-3,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$12.72 - $16.16 $6,360 - $8,080	500 Added 20.0%	3,000 $45,000
Q2 2020 Aug 14, 2020	BUY	$12.39 - $17.33 $30,975 - $43,324	2,500 New	2,500 $44,000
Q4 2019 Feb 14, 2020	SELL	$16.11 - $25.98 $72,495 - $116,910	-4,500 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$17.68 - $21.57 $7,072 - $8,628	-400 Reduced 8.16%	4,500 $97,000
Q4 2018 Feb 13, 2019	BUY	$12.45 - $23.47 $17,430 - $32,858	1,400 Added 40.0%	4,900 $64,000
Q3 2018 Nov 15, 2018	BUY	$17.57 - $23.95 $17,570 - $23,950	1,000 Added 40.0%	3,500 $84,000
Q2 2018 Aug 13, 2018	BUY	$11.6 - $19.27 $27,840 - $46,248	2,400 Added 2400.0%	2,500 $48,000
Q1 2018 May 15, 2018	BUY	$11.77 - $16.08 $1,177 - $1,607	100 New	100 $1,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $14.5M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.